Should COVID-19 be branded to Viral Thrombotic Fever?
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/46941 |
Resumo: | Hospital Pró-Cardíaco. Founder and coordinator of Department of Critical Care. Americas Medical Services. United Health Group. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_a97bdebcddcb15f3a0e8446f6399822d |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/46941 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Costa Filho, R. C.Faria Neto, Hugo Caire C.Mengel, J.Pelajo-Machado, M.Martins, M. A.Leite, E. T.Mendonça Filho, H. T. F.Souza, T. A. C. Brasil deBentacor, G. B.Galiardi, J. P. Leite2021-04-27T19:00:02Z2021-04-27T19:00:02Z2021COSTA FILHO, R. C. et al. Should COVID-19 be branded to Viral Thrombotic Fever? Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, p. 1-27, 2021.0074-0276https://www.arca.fiocruz.br/handle/icict/4694110.1590/0074-027602005521678-8060engFundação Oswaldo Cruz. Instituto Oswaldo Cruz.COVID-19SARS-CoV-2FebreSARS COV MproEndotélioInflamaçãoCoagulaçãoTromboseHipercoagulabilidadeEndotheliumCOVID-19SARS-CoV-2FeverNETsInflammationCoagulationroTEMHypercoagulabilityThrombosisShould COVID-19 be branded to Viral Thrombotic Fever?info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHospital Pró-Cardíaco. Founder and coordinator of Department of Critical Care. Americas Medical Services. United Health Group. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / UNIFASE. Faculdade de Medicina. Petrópolis, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Patologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.Instituto Nacional do Câncer. Rio de Janeiro, RJ, Brasil.Políticas de Saúde – UHG (UnitedHealth Group). BrasilFundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Proteômica Estrutural e Computacional. Curitiba, PR, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS & Imunologia Molecular. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratorio de Virologia Comparada e Ambiental. Rio de Janeiro, RJ, Brasil.Coronaviruses can cause a diverse array of clinical manifestations, from fever with symptoms of the common cold to highly lethal Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). SARS-CoV-2, the coronavirus discovered in Hubei province, China, at the end of 2019, became known worldwide for causing COVID-19. Over one time-period, the scientific community has produced a large bulk of knowledge about this disease and countless reports about its immune-pathological aspects. This knowledge, including data obtained in postmortem studies, points unequivocally to a hypercoagulability state. However, the name COVID 19 tells us very little about the true meaning of the disease. Our proposal is more comprehensive; it intends to frame COVID-19 in more clinical terminology, making an analogy to Viral Hemorrhagic Fever (VHF). Thus, we found irrefutable evidence in the current literature that COVID-19 is the first viral disease that can be branded as a Viral Thrombotic Fever. This manuscript points out that SARS CoV-2 goes far beyond pneumonia or SARS. COVID-19 infections promote remarkable interactions among the endothelium, coagulation, and immune response, building up a background capable of promoting a “thrombotic storm,” much more than a “cytokine storm.” The importance of a viral protease called main protease (Mpro) is highlighted as a key component for SARS-CoV-2 replication in the host cell. A deeper analysis of this protease and its importance on the coagulation system is also discussed for the first time, mainly because of its similarity with the thrombin and factor Xa molecules, as recently pointed out by structural comparison of crystallographic structures.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/46941/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALHugoCCneto_josePauloGLiete_etal_IOC_2021.pdfHugoCCneto_josePauloGLiete_etal_IOC_2021.pdfapplication/pdf267692https://www.arca.fiocruz.br/bitstream/icict/46941/2/HugoCCneto_josePauloGLiete_etal_IOC_2021.pdf34a760dca5f253548e9dec163317cb12MD52TEXTHugoCCneto_josePauloGLiete_etal_IOC_2021.pdf.txtHugoCCneto_josePauloGLiete_etal_IOC_2021.pdf.txtExtracted texttext/plain42918https://www.arca.fiocruz.br/bitstream/icict/46941/3/HugoCCneto_josePauloGLiete_etal_IOC_2021.pdf.txt8cf7fbd6aaf869caf5873a069a118b8cMD53icict/469412021-04-29 00:37:38.341oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-04-29T03:37:38Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| title |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| spellingShingle |
Should COVID-19 be branded to Viral Thrombotic Fever? Costa Filho, R. C. COVID-19 SARS-CoV-2 Febre SARS COV Mpro Endotélio Inflamação Coagulação Trombose Hipercoagulabilidade Endothelium COVID-19 SARS-CoV-2 Fever NETs Inflammation Coagulation roTEM Hypercoagulability Thrombosis |
| title_short |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| title_full |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| title_fullStr |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| title_full_unstemmed |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| title_sort |
Should COVID-19 be branded to Viral Thrombotic Fever? |
| author |
Costa Filho, R. C. |
| author_facet |
Costa Filho, R. C. Faria Neto, Hugo Caire C. Mengel, J. Pelajo-Machado, M. Martins, M. A. Leite, E. T. Mendonça Filho, H. T. F. Souza, T. A. C. Brasil de Bentacor, G. B. Galiardi, J. P. Leite |
| author_role |
author |
| author2 |
Faria Neto, Hugo Caire C. Mengel, J. Pelajo-Machado, M. Martins, M. A. Leite, E. T. Mendonça Filho, H. T. F. Souza, T. A. C. Brasil de Bentacor, G. B. Galiardi, J. P. Leite |
| author2_role |
author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Costa Filho, R. C. Faria Neto, Hugo Caire C. Mengel, J. Pelajo-Machado, M. Martins, M. A. Leite, E. T. Mendonça Filho, H. T. F. Souza, T. A. C. Brasil de Bentacor, G. B. Galiardi, J. P. Leite |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 SARS-CoV-2 Febre SARS COV Mpro Endotélio Inflamação Coagulação Trombose Hipercoagulabilidade |
| topic |
COVID-19 SARS-CoV-2 Febre SARS COV Mpro Endotélio Inflamação Coagulação Trombose Hipercoagulabilidade Endothelium COVID-19 SARS-CoV-2 Fever NETs Inflammation Coagulation roTEM Hypercoagulability Thrombosis |
| dc.subject.en.pt_BR.fl_str_mv |
Endothelium COVID-19 SARS-CoV-2 Fever NETs Inflammation Coagulation roTEM Hypercoagulability Thrombosis |
| description |
Hospital Pró-Cardíaco. Founder and coordinator of Department of Critical Care. Americas Medical Services. United Health Group. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2021 |
| dc.date.accessioned.fl_str_mv |
2021-04-27T19:00:02Z |
| dc.date.available.fl_str_mv |
2021-04-27T19:00:02Z |
| dc.date.issued.fl_str_mv |
2021 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
COSTA FILHO, R. C. et al. Should COVID-19 be branded to Viral Thrombotic Fever? Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, p. 1-27, 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/46941 |
| dc.identifier.issn.pt_BR.fl_str_mv |
0074-0276 |
| dc.identifier.doi.pt_BR.fl_str_mv |
10.1590/0074-02760200552 |
| dc.identifier.eissn.none.fl_str_mv |
1678-8060 |
| identifier_str_mv |
COSTA FILHO, R. C. et al. Should COVID-19 be branded to Viral Thrombotic Fever? Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, p. 1-27, 2021. 0074-0276 10.1590/0074-02760200552 1678-8060 |
| url |
https://www.arca.fiocruz.br/handle/icict/46941 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. |
| publisher.none.fl_str_mv |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/46941/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/46941/2/HugoCCneto_josePauloGLiete_etal_IOC_2021.pdf https://www.arca.fiocruz.br/bitstream/icict/46941/3/HugoCCneto_josePauloGLiete_etal_IOC_2021.pdf.txt |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 34a760dca5f253548e9dec163317cb12 8cf7fbd6aaf869caf5873a069a118b8c |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009235365068800 |